SIENI Holdings
SIENI Holdings is a pioneering biotech company focused on developing localized therapies for the treatment of musculoskeletal conditions, including inflammation, infection, pain, and the prevention of post-surgical complications. Their mission is to enable faster healing and safer recovery by minimizing systemic drug exposure through their innovative AEGEAL platform, which delivers FDA-approved drugs directly to the site of injury or surgery. SIENI's vision is to provide versatile, precise, and bioresponsive solutions adaptable across orthopedic, trauma, burn, and veterinary applications, addressing a significant global health burden and market opportunity.
What We Do
A first-in-class, injectable gel delivery platform developed with validated nanotechnology for localized, sustained, and controlled delivery of FDA-approved drugs directly to injured tissue. AEGEAL is adaptable across orthopedic, trauma, burn, and other applications, with potential for both human and veterinary use.
Development of therapies for inflammation, infection, pain, and prevention of post-surgical complications in musculoskeletal diseases, utilizing localized drug delivery to minimize systemic exposure.
Application Area
Show More (4)Battlefield Resuscitation
Regenerative Medicine
Key People
Fractional CCO/CBO
News & Updates
Welcome to WordPress. This is your first post. Edit or delete it, then start writing!